Boston Scientific Corporation (LON:0HOY)
London · Delayed Price · Currency is GBP · Price in USD | Market Cap | 58.13B -48.7% |
| Revenue (ttm) | 15.61B +17.4% |
| Net Income | 2.70B +75.4% |
| EPS | 1.81 +74.4% |
| Shares Out | n/a |
| PE Ratio | 21.53 |
| Forward PE | 15.34 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 20 |
| Average Volume | 17,697 |
| Open | 54.10 |
| Previous Close | 54.21 |
| Day's Range | 54.00 - 54.30 |
| 52-Week Range | 53.23 - 109.51 |
| Beta | 0.62 |
| RSI | 33.85 |
| Earnings Date | Apr 22, 2026 |
About Boston Scientific
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. The company operates in two segments, MedSurg and Cardiovascular. It offers devices to diagnose and treat a range of gastrointestinal conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, SpyGlass, single-use scopes used for diagnostic and therapeutic procedures in the pancreaticobiliary system, in endoscopic retrograde cholangiopancreatogra... [Read more]
Financial Performance
In 2025, Boston Scientific's revenue was $20.07 billion, an increase of 19.87% compared to the previous year's $16.75 billion. Earnings were $2.90 billion, an increase of 56.40%.
Financial numbers in USD Financial StatementsNews
Belo Sun to Commence Technical Studies on Volta Grande Gold Project
TORONTO, May 12, 2026 (GLOBE NEWSWIRE) -- Belo Sun Mining Corp. (“Belo Sun” or “Company”) (TSX: BSX, OTCQB: BSXGF) today announces the commencement of technical studies relating to its Volta Grande Go...
Boston Scientific issues correction for ACCOLADE pacemakers, FDA says
The FDA is aware that Boston Scientific (BSX) has issued a letter to affected customers recommending all ACCOLADE pacemakers and CRT-Ps be corrected prior to continued use, the agency announced.
US FDA issues recall of Boston Scientific heart devices
Boston Scientific has issued an urgent recall to correct several heart devices after the U.S. Food and Drug Administration classified the action as its most serious recall, the regulator said on Thu...
Belo Sun Mining Corp. Begins Trading on OTCQX
TORONTO, May 07, 2026 (GLOBE NEWSWIRE) -- Belo Sun Mining Corp. (“Belo Sun” or the “Company”) (TSX: BSX; OTCQX: BSXGF) is pleased to announce that effective today, its common shares have qualified to ...
Penumbra, Inc. Reports First Quarter 2026 Financial Results
ALAMEDA, Calif., May 6, 2026 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, today reported financial results for the first quarter ended March 31, 2026.
Boston Scientific announces participation in Bernstein's 42nd Annual Strategic Decisions Conference and conference call discussing second quarter 2026 results
MARLBOROUGH, Mass., May 4, 2026 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will participate in Bernstein's 42nd Annual Strategic Decisions Conference on Wednesday, May 27, 2026.
Belo Sun Provides Update on Volta Grande Gold Project
TORONTO, April 30, 2026 (GLOBE NEWSWIRE) -- Belo Sun Mining Corp. (“Belo Sun” or “Company”) (TSX: BSX, OTCQB: BSXGF) today announces an update on recent developments relating to its Volta Grande Gold ...
Boston Scientific Transcript: AGM 2026
The meeting reviewed strong 2025 financial results, strategic growth initiatives, and board updates. All directors were re-elected, and most company proposals passed, but neither proposal to lower the threshold for calling special shareholder meetings was approved. Litigation risks were addressed.
Procedure using Boston Scientific device tops medication for heart rhythm problem
We also report below on early data that poses a possible solution to a devastating pregnancy complication, and a potential breakthrough treatment for liver transplant patients.
Boston Scientific downgraded to Neutral from Outperform at Daiwa
Daiwa downgraded Boston Scientific (BSX) to Neutral from Outperform with a price target of $60, down from $83.
Boston Scientific price target lowered to $95 from $115 at Argus
Argus lowered the firm’s price target on Boston Scientific (BSX) to $95 from $115 but keeps a Buy rating on the shares after its Q1 results and guidance cut. The…
Boston Scientific announces data on Farapulse PFA Platform, Watchman LAAC
Boston Scientific (BSX) announced data supporting use of the company’s Farapulse Pulsed Field Ablation, PFA, Platform and Watchman Left Atrial Appendage Closure, LAAC, technologies. All data were pres...
Data at Heart Rhythm 2026 highlight key Boston Scientific therapies
Positive data for FARAPULSE™ Pulsed Field Ablation and WATCHMAN™ LAAC Devices underscore therapy safety and effectiveness in late-breaking clinical trial sessions MARLBOROUGH, Mass. and CHICAGO, Apri...
Boston Scientific put volume heavy and directionally bearish
Bearish flow noted in Boston Scientific (BSX) with 8,404 puts trading, or 1.2x expected. Most active are Jul-26 60 puts and Jun-26 60 puts, with total volume in those strikes…
Boston Scientific price target lowered to $100 from $105 at RBC Capital
RBC Capital lowered the firm’s price target on Boston Scientific (BSX) to $100 from $105 and keeps an Outperform rating on the shares. The stock rose after the company’s Q1…
Boston Scientific price target lowered to $90 from $100 at Oppenheimer
Oppenheimer lowered the firm’s price target on Boston Scientific (BSX) to $90 from $100 and keeps an Outperform rating on the shares. The firm cites the company’s Q1 results and…
Boston Scientific price target lowered to $77 from $97 at Needham
Needham analyst Mike Matson lowered the firm’s price target on Boston Scientific (BSX) to $77 from $97 and keeps a Buy rating on the shares.
Boston Scientific price target lowered to $71 from $109 at Canaccord
Canaccord analyst William Plovanic lowered the firm’s price target on Boston Scientific (BSX) to $71 from $109 and keeps a Buy rating on the shares. The firm noted they reported…
Boston Scientific price target lowered to $85 from $90 at Truist
Truist lowered the firm’s price target on Boston Scientific (BSX) to $85 from $90 and keeps a Buy rating on the shares after its Q1 results. The company saw decelerating…
Boston Scientific upgraded to Buy from Hold at Nephron Research
Nephron Research analyst Chris Pasquale upgraded Boston Scientific (BSX) to Buy from Hold with an unchanged price target of $85 post the Q1 report. The company reset expectations, which “clears…
Boston Scientific price target lowered to $78 from $86 at Baird
Baird lowered the firm’s price target on Boston Scientific (BSX) to $78 from $86 and keeps an Outperform rating on the shares. The firm updated its model following quarterly results…
Boston Scientific price target lowered to $75 from $94 at Wells Fargo
Wells Fargo lowered the firm’s price target on Boston Scientific (BSX) to $75 from $94 and keeps an Overweight rating on the shares. The firm notes the company delivered Q1…
Boston Scientific price target lowered to $96 from $100 at Barclays
Barclays analyst Matt Miksic lowered the firm’s price target on Boston Scientific (BSX) to $96 from $100 and keeps an Overweight rating on the shares. The firm cites the company’s…
Boston Scientific price target lowered to $84 from $87 at Goldman Sachs
Goldman Sachs analyst David Roman lowered the firm’s price target on Boston Scientific (BSX) to $84 from $87 but keeps a Buy rating on the shares after its Q1 results.
Boston Scientific price target lowered to $100 from $110 at Jefferies
Jefferies lowered the firm’s price target on Boston Scientific (BSX) to $100 from $110 and keeps a Buy rating on the shares following first quarter results. While Q1 was better…